{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:22:50Z","timestamp":1773660170212,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.vaccine.2010.05.060","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T09:01:27Z","timestamp":1276160487000},"page":"5265-5271","source":"Crossref","is-referenced-by-count":21,"title":["Chimeric antibodies against tick-borne encephalitis virus"],"prefix":"10.1016","volume":"28","author":[{"given":"Lev N.","family":"Levanov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid E.","family":"Matveev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena P.","family":"Goncharova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid R.","family":"Lebedev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander B.","family":"Ryzhikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana E.","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana A.","family":"Batanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander N.","family":"Shvalov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan K.","family":"Baykov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyudmila N.","family":"Shingarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Kirpichnikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina V.","family":"Tikunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9627","key":"10.1016\/j.vaccine.2010.05.060_bib1","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(08)60800-4","article-title":"Tick-borne encephalitis","volume":"371","author":"Lindquist","year":"2008","journal-title":"Lancet"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2010.05.060_bib2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2006.01.026","article-title":"Engineering of therapeutic antibodies to minimize immunogenicity and optimize function","volume":"58","author":"Presta","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2010.05.060_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2144\/00291ov01","article-title":"Antibody engineering at the millennium","volume":"29","author":"Gavilondo","year":"2000","journal-title":"Biotechniques"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2010.05.060_bib4","first-page":"33","article-title":"Monoclonal and recombinant antibodies, 30 years after\u2026","volume":"14","author":"Laffly","year":"2005","journal-title":"Hum Antibodies"},{"issue":"1","key":"10.1016\/j.vaccine.2010.05.060_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0168-1702(93)90011-B","article-title":"Epitope analysis of tick-borne encephalitis (TBE) complex viruses using monoclonal antibodies to envelope glycoprotein of TBE virus (persulcatus subtype)","volume":"30","author":"Tsekhanovskaya","year":"1993","journal-title":"Virus Res"},{"issue":"2","key":"10.1016\/j.vaccine.2010.05.060_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.virusres.2005.04.007","article-title":"Steps of the tick-borne encephalitis virus replication cycle that affect neuropathogenesis","volume":"111","author":"Mandl","year":"2005","journal-title":"Virus Res"},{"issue":"1","key":"10.1016\/j.vaccine.2010.05.060_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1385\/MB:26:1:39","article-title":"Generation and production of engineered antibodies","volume":"26","author":"Kipriyanov","year":"2004","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2010.05.060_bib8","unstructured":"Netesova NA, Belavin PA, Malygin EG, Rukavishnikov MIu. Recombinant plasmid PGSDEI, encoding protein E of tick-borne encephalitis virus and strain Escherichia coli \u2013 producer of recombinant protein E of tick-borne encephalitis virus. The patent of Russian Federation. No. 2136754.1999."},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2010.05.060_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0022-1759(99)00184-2","article-title":"Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3\u2032 to 5\u2032 exonuclease activity","volume":"233","author":"Wang","year":"2000","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2010.05.060_bib10","first-page":"598","article-title":"Recombinant full-size human antibody to Ebola virus","volume":"33","author":"Shingarova","year":"2007","journal-title":"Bioorg Khim"},{"issue":"5259","key":"10.1016\/j.vaccine.2010.05.060_bib11","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2010.05.060_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0022-1759(87)90187-6","article-title":"Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay","volume":"100","author":"Beatty","year":"1987","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.vaccine.2010.05.060_bib13","first-page":"50","article-title":"Preparation and study of properties of anti-idiotypic antibodies, carrying hemagglutinating paratopes of tick-borne encephalitis virus on their surface","volume":"41","author":"Protopopova","year":"1996","journal-title":"Vopr Virusol"},{"key":"10.1016\/j.vaccine.2010.05.060_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-59745-554-1_1","article-title":"Therapeutic antibodies: current state and future trends \u2013 is a paradigm change coming soon?","volume":"525","author":"Dimitrov","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.05.060_bib15","first-page":"694","article-title":"Monoclonal antibodies against tick-borne encephalitis virus glycoprotein: preliminary characterization","volume":"34","author":"Matveev","year":"1989","journal-title":"Vopr Virusol"},{"issue":"12","key":"10.1016\/j.vaccine.2010.05.060_bib16","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.vaccine.2010.05.060_bib17","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1128\/JVI.00291-08","article-title":"Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo","volume":"82","author":"Goncalvez","year":"2008","journal-title":"J Virol"},{"issue":"23","key":"10.1016\/j.vaccine.2010.05.060_bib18","doi-asserted-by":"crossref","first-page":"14606","DOI":"10.1128\/JVI.79.23.14606-14613.2005","article-title":"Protective and therapeutic capacity of human single-chain Fv\u2013Fc fusion proteins against West Nile virus","volume":"79","author":"Gould","year":"2005","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2010.05.060_bib19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1349-7006.2001.tb02155.x","article-title":"Phage display cloning and characterization of monoclonal antibody genes and recombinant Fab fragment against the CD98 oncoprotein","volume":"92","author":"Itoh","year":"2001","journal-title":"Jpn J Cancer Res"},{"issue":"6","key":"10.1016\/j.vaccine.2010.05.060_bib20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00705-006-0923-8","article-title":"Neutralization of animal virus infectivity by antibody","volume":"152","author":"Reading","year":"2007","journal-title":"Arch Virol"},{"issue":"Pt6","key":"10.1016\/j.vaccine.2010.05.060_bib21","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1099\/vir.0.80912-0","article-title":"Chimeric monoclonal antibodies to hypervariable region 1 of hepatitis C virus","volume":"86","author":"Li","year":"2005","journal-title":"J Gen Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.05.060_bib22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/sj.bjc.6602470","article-title":"Engineering and characterization of chimeric monoclonal antibody 806 (ch806) for the targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR","volume":"92","author":"Panousis","year":"2005","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.vaccine.2010.05.060_bib23","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse\u2013human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2010.05.060_bib24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2007.11.046","article-title":"After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment","volume":"26","author":"Br\u00f6ker","year":"2008","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10007693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10007693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:41:54Z","timestamp":1559176914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10007693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":24,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0264410X10007693"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.05.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}